• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life sciences >The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia
【24h】

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

机译：非典型抗精神病药对首次发作，未接受过药物治疗的精神分裂症患者内脏脂肪分布的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to determine the location of antipsychotic-induced weight gain in drug naive, first episode patients with schizophrenia. Various fatness and fat distribution parameters (by Computerized Tomography scanning and anthropometry) and 1600 hr plasma cortisol were measured in 19 (15 men and 4 women) subjects with schizophrenia (mean age = 31.0 years; mean body mass index [BMI] = 24.6 kg/m(2)) and an equal number of age- and sex- matched controls (mean age = 32.6 yr; mean BMI = 23.0 kg/m(2)). Patients were then given either olanzapine or risperidone. Sixteen patients were re-tested following a treatment period lasting approximately 6 months. Patients with schizophrenia, had significantly more intra-abdmonial fat [IAF] (116.8 +/- 20.2 cm(2) vs. 38.0 +/- 4.8 cm(2), respectively; t = 3.80, df = 18, p < 0.0001) and had higher levels of plasma cortisol (360.2 +/- 49.6 nmol/L vs. 192.7 +/- 19.7 nmol/L, respectively; t = 3.13, df = 18, p < 0.003) than appropriately matched control subjects. Treatment with atypical antipsychotics did not result in a significant increase in IAF (116.8 +/- 20.2 cm(2) vs. 131.7 +/- 20.9 cm(2); p = NS) though visceral fat stores still remained significantly higher than those seen in controls (38.0 +/- 4.8 cm(2)) (F = 9.34; df = 2, 51; p < 0.0003). However, plasma levels of cortisol did significantly decrease (360.2 +/- 49.6 nmol/L +/- vs. 316.2 +/- 48.4 nmol/L; p < 0.05). Pre-treatment levels of IAF did not differ between those who received risperidone and those who were given olanzapine (123.0 +/- 35.9 cm(2) vs. 113.1 +/- 15.7 cm(2), respectively; t = 0.20, df = 16, p < 0.84). The increase in IAF did not differ between those given risperidone and those who received olanzapine (26.9 +/- 12.1 cm(2) vs. 18.24 +/- 11.44 cm(2), respectively; t = 0.50, df = 16, p < 0.63). Patients with drug naive, first episode, schizophrenia have higher levels of visceral fats stores as compared to matched control subjects. Treatment with atypical antipsychotics does not result in a significant increase in IAF distribution. (C) 2003 Elsevier Inc. All rights reserved. [References: 48]
机译：这项研究的目的是确定在单纯性精神分裂症首发患者中抗精神病药物引起的体重增加的位置。在精神分裂症（平均年龄= 31.0岁;平均体重指数[BMI] = 24.6 kg）的19位（15位男性和4位女性）受试者中测量了各种脂肪和脂肪分布参数（通过计算机断层扫描和人体测量）和1600小时血浆皮质醇。 / m（2））和相等数量的年龄和性别匹配的对照者（平均年龄= 32.6岁;平均BMI = 23.0 kg / m（2））。然后给患者服用奥氮平或利培酮。在持续约6个月的治疗期后，对16位患者进行了重新测试。精神分裂症患者的腹内脂肪[IAF]明显更多（分别为116.8 +/- 20.2 cm（2）和38.0 +/- 4.8 cm（2）; t = 3.80，df = 18，p <0.0001）血浆皮质醇水平较高（分别为360.2 +/- 49.6 nmol / L和192.7 +/- 19.7 nmol / L; t = 3.13，df = 18，p <0.003）。尽管内脏脂肪存储仍显着高于所观察到的值，但非典型抗精神病药的治疗并未导致IAF显着增加（116.8 +/- 20.2 cm（2）与131.7 +/- 20.9 cm（2）; p = NS）在对照（38.0 +/- 4.8 cm（2））中（F = 9.34; df = 2，51; p <0.0003）。但是，血浆皮质醇水平确实显着降低（360.2 +/- 49.6 nmol / L +/-与316.2 +/- 48.4 nmol / L; p <0.05）。接受利培酮治疗的患者和接受奥氮平治疗的患者的IAF治疗前水平无差异（分别为123.0 +/- 35.9 cm（2）和113.1 +/- 15.7 cm（2）; t = 0.20，df = 16，p ＜0.84）。给予利培酮和接受奥氮平的患者之间IAF的增加无差异（分别为26.9 +/- 12.1 cm（2）和18.24 +/- 11.44 cm（2）; t = 0.50，df = 16，p < 0.63）。与匹配的对照组相比，天真的药物，首发精神分裂症的患者的内脏脂肪储存水平更高。用非典型抗精神病药治疗不会导致IAF分布明显增加。 （C）2003 Elsevier Inc.保留所有权利。 [参考：48]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号